CERo Therapeutics Holdings, Inc. (CERO)

NASDAQ: CERO · IEX Real-Time Price · USD

0.200

-0.043 (-17.66%)

At close: Jul 19, 2024, 4:00 PM

0.194

-0.006 (-3.00%)

Pre-market: Jul 22, 2024, 9:17 AM EDT

CERO Employees

As of December 31, 2023, CERo Therapeutics Holdings had 9 total employees, including 8 full-time and 1 part-time employees.

Employees

9

Change

n/a

Growth

n/a

Revenue / Employee

n/a

Profits / Employee

n/a

Market Cap

4.17M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	9	-	-

Related Stocks

Company Name	Employees
China Pharma Holdings	231
OpGen	100
Genprex	26
Trevena	23
Sonnet BioTherapeutics Holdings	12
Palisade Bio	9
Allarity Therapeutics	6
MyMD Pharmaceuticals	6

Employee Rankings

CERO News

4 days ago - Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July - Benzinga
5 weeks ago - CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236 - GlobeNewsWire
2 months ago - CERo Therapeutics, Inc. Provides Corporate Update for Shareholders - GlobeNewsWire
4 months ago - CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients - Business Wire
5 months ago - Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. Announce Close of Business Combination - Business Wire
1 year ago - CERo Therapeutics, Inc. and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Advancing the Development of Next Generation Engineered T Cell Therapeutics - Business Wire
1 year ago - Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Mutually Agree to Terminate Business Combination Agreement - GlobeNewsWire
1 year ago - Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Leveraging Human Milk Biology to Treat Gut-Brain Axis Disorders - GlobeNewsWire